PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Transfusion”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 397 records · Page 22Linked to original sources
PubMed1994

[Screening for post-transfusion hepatitis C-importance of enrollment and recall of blood transfusion recipients].

OBJECTIVE: To detect chronic hepatitis C virus infection in recipients of blood products. DESIGN: Retrospective analysis by recall and enrollment of recipients. PATIENTS AND METHODS: Two-hundred twenty-six patients who received blood products in Tokushima for open heart surgery from January 1993 to December 1992 were examined for HCV antibodies by second-generation assay and surrogate markers. RESULTS: Twenty two (14%) of the 161 patients who received blood products before Nov 1989 had detectable HCV antibodies, but none of the 65 recipients receiving blood after 1990, the year the blood bank began to screen for HCV-antibody. Of 22 seropositive patients, HCV RNA (ribonucleic acid) was recognized in 10 (45%) by HCV PCR (polymerase chain reaction) method, indicating persistent HCV infection. Moreover, abnormal alanine aminotransferase (ALT), more than 25 IU/l, during the chronic phase of HCV infection was recognized in 9 of 10 patients with detectable HCV RNA, but none in patients with undetectable HCV RNA. In the 15 patients in whom liver biopsy was performed, 10 had abnormal histology; 4 chronic active hepatitis, 6 chronic persistent hepatitis, and 5 had normal histology. CONCLUSION: It is Important to recall and screen for chronic hepatitis C In blood product recipients, since persistent and active HCV infection is often assymptomatic, yet treatable.

Blood Component Transfusion↗
PubMed1998

[Detection of the nucleic acids of hepatitis B and C viruses and human immunodeficiency virus for the biological screening of blood donations. Viral Hepatitis and Retrovirus Working Groups and Subgroup for Molecular Biology Applied to Transfusion Virology of the French Blood Transfusion Society].

Direct viral DNA or RNA detection by genomic amplification methods should contribute to the improvement of blood supply safety by reducing the pre-seroconversion window period. However, nucleic acid testing may not eliminate virus transmission from window period donations. Moreover, the virus subtype diversity has to be taken into account for the choice of nucleic amplification assays. Technology for nucleic acid testing has not been developed to be implemented in blood screening laboratories. The limitations of these procedures are mainly linked to the difficulties related to the automation of sample processing and to the possibilities of cross contamination of samples due to the high sensitivity of amplification methods. The extreme complexity of nucleic acid testing for single donation screening (development of an on-site automated high-throughput instrumentation, training, specialized facilities for sample processing, amplification and detection...) and its high cost mean that strategies using amplification testing of pooled samples should be developed.

AIDS Serodiagnosis↗